Business, energy, technology, markets and global industry news from Business News Today

Veloxis Pharmaceuticals

PharmaDeviceNews Veloxis Pharmaceuticals
Asahi Kasei expands antiviral portfolio with FDA-approved Hovilpri treatment
Medical Devices & Diagnostics

Asahi Kasei’s Hovilpri wins FDA approval after PRIOH-1 trial demonstrates superior lesion healing

FDA approves Hovilpri for refractory HSV after 63% lesion healing in Phase 3. See how pritelivir changes treatment and Asahi Kasei's outlook.

Read More
Veloxis Pharmaceuticals’ more than $46 million Envarsus XR kickback resolution brings pharmaceutical marketing practices, federal compliance oversight and the company’s five-year corporate integrity obligations into focus. Representative image.
Pharma & Biotech

What the $46m Veloxis Pharmaceuticals settlement means for Envarsus XR

Veloxis Pharmaceuticals will pay over $46 million over Envarsus XR conduct. See why five years of compliance oversight could matter even more.

Read More
Pharma & Biotech

Veloxis Pharmaceuticals’ pegrizeprument gets orphan status—will FDA incentives accelerate clinical momentum?

Veloxis earns FDA orphan status for pegrizeprument in liver transplant rejection. Find out what this means for the future of immunosuppressive therapy.

Read More